2011.01.03 Weekly Broadcast Email
The following updates were made to the CCCWFU CCOP Research Base website for the week of January 3, 2011.
The following adverse events were received during the month of December. They have been attached to this email and summarized on the Adverse Event webpage.
In the month of December, 6 patients were accrued to CCCWFU CCOP Research Base trials. WFU was the top accruing site with 3 patients. See the Research Base website spotlight section for further information.
98308:(A Phase III Randomized, Double-Blind, Placebo Controlled Trial of North American Ginseng Extract (CVT-E002; COLD-fX®) to Prevent Respiratory Infection and Reduce Antibiotic Use in Patients with Chronic Lymphocytic Leukemia)
Amendment 7 has been added to the website. This amendment includes study staff changes only, no consent form changes.
97509: (A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue)
As a reminder, staff must be certified to administer the neurocognitive testing before patients can be registered to this study. Consider completing certification while this study is being approved by your local IRB. Please see Section 7.6 of the protocol for specific certification requirements.
Wake Forest University Baptist Medical Center
Department of Radiation Oncology
Research Base Protocol Information Office
2000 West First Street, Suite 401
Winston-Salem, NC 27104
Pager: 336-716-2440, ID number 1689
CONFIDENTIAL AND PRIVILEGED: The information contained in this electronic message may be privileged and confidential information intended for the sole use of the addressee and any personnel receiving a copy. If the reader of this electronic message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this electronic message in error, please notify me immediately by responding to this message.
WITHHOLD FROM PUBLIC DISCLOSURE UNDER N.C.G.S. 104E-9(a)(4)